US Stock MarketDetailed Quotes

SONN Sonnet BioTherapeutic

Watchlist
  • 1.5900
  • +0.0500+3.25%
Close Feb 14 16:00 ET
4.87MMarket Cap-0.15P/E (TTM)

Sonnet BioTherapeutic Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Quarterly+Annual
YOY yoy
Hide blank lines yoy
(Q1)Dec 31, 2024
(FY)Sep 30, 2024
(Q4)Sep 30, 2024
(Q3)Jun 30, 2024
(Q2)Mar 31, 2024
(Q1)Dec 31, 2023
(FY)Sep 30, 2023
(Q4)Sep 30, 2023
(Q3)Jun 30, 2023
(Q2)Mar 31, 2023
Total revenue
5,268.84%1M
-87.40%18.63K
0
0
0
-50.00%18.63K
-57.76%147.81K
-40.63%37.26K
-40.63%36.85K
-61.77%36.45K
Operating revenue
5,268.84%1M
-87.40%18.63K
--0
--0
--0
-50.00%18.63K
-57.76%147.81K
-40.63%37.26K
-40.63%36.85K
-61.77%36.45K
Cost of revenue
Gross profit
Operating expense
196.68%3.85M
-37.34%11.87M
-12.76%3.17M
-10.72%3.53M
-32.14%3.87M
-77.03%1.3M
-36.91%18.94M
-51.11%3.64M
-50.16%3.95M
-31.36%5.7M
Selling and administrative expenses
200.46%1.96M
-13.96%6.13M
10.01%1.97M
16.79%1.8M
-9.73%1.7M
-65.67%653.46K
-16.90%7.13M
-22.50%1.79M
-32.35%1.54M
-0.83%1.88M
-General and administrative expense
200.46%1.96M
-13.96%6.13M
10.01%1.97M
16.79%1.8M
-9.73%1.7M
-65.67%653.46K
-16.90%7.13M
-22.50%1.79M
-32.35%1.54M
-0.83%1.88M
Research and development costs
192.85%1.89M
-51.44%5.74M
-34.94%1.2M
-28.32%1.73M
-43.21%2.17M
-82.81%644.04K
-44.90%11.81M
-64.04%1.84M
-57.35%2.41M
-40.41%3.82M
Operating profit
-122.81%-2.85M
36.95%-11.85M
11.85%-3.17M
9.88%-3.53M
31.71%-3.87M
77.21%-1.28M
36.66%-18.79M
51.20%-3.6M
50.23%-3.92M
31.00%-5.66M
Net non-operating interest income expense
Other net income (expense)
-238.53%-152.88K
11,109.40%4.41M
158.47%44.78K
173.52%23.11K
183,946.55%4.23M
57.09%110.36K
23.64%-40.08K
-31.21%-76.59K
-220.93%-31.43K
-234.13%-2.3K
Gain on sale of security
-238.53%-152.88K
310.33%84.29K
158.47%44.78K
173.52%23.11K
-3,979.90%-93.96K
57.09%110.36K
23.64%-40.08K
-31.21%-76.59K
-220.93%-31.43K
-234.13%-2.3K
Other non- operating income (expenses)
----
--4.33M
--0
----
--4.33M
----
----
----
----
----
Income before tax
-156.93%-3M
60.51%-7.44M
14.91%-3.13M
11.18%-3.51M
106.45%365.43K
78.92%-1.17M
36.64%-18.83M
50.55%-3.68M
49.90%-3.95M
30.96%-5.67M
Income tax
158.4K
0
Net income
-170.49%-3.16M
60.51%-7.44M
14.91%-3.13M
11.18%-3.51M
106.45%365.43K
78.92%-1.17M
36.64%-18.83M
50.55%-3.68M
49.90%-3.95M
30.96%-5.67M
Net income continuous Operations
-170.49%-3.16M
60.51%-7.44M
14.91%-3.13M
11.18%-3.51M
106.45%365.43K
78.92%-1.17M
36.64%-18.83M
50.55%-3.68M
49.90%-3.95M
30.96%-5.67M
Minority interest income
Net income attributable to the parent company
-170.49%-3.16M
60.51%-7.44M
14.91%-3.13M
11.18%-3.51M
106.45%365.43K
78.92%-1.17M
36.64%-18.83M
50.55%-3.68M
49.90%-3.95M
30.96%-5.67M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders
-170.49%-3.16M
60.51%-7.44M
14.91%-3.13M
11.18%-3.51M
106.45%365.43K
78.92%-1.17M
36.64%-18.83M
50.55%-3.68M
49.90%-3.95M
30.96%-5.67M
Basic earnings per share
36.59%-1.56
92.18%-11.35
78.16%-3.67
76.27%-5.6
101.06%0.64
98.25%-2.46
87.95%-145.13
94.29%-16.8039
92.63%-23.6
82.03%-60.4
Diluted earnings per share
36.59%-1.56
92.18%-11.35
78.16%-3.67
76.27%-5.6
100.93%0.56
98.25%-2.46
87.95%-145.13
94.29%-16.8039
92.63%-23.6
82.03%-60.4
Dividend per share
Currency Unit
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
Accounting Standards
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
Audit Opinions
--
Unqualified Opinion with Explanatory Notes
--
--
--
--
Unqualified Opinion with Explanatory Notes
--
--
--
(Q1)Dec 31, 2024(FY)Sep 30, 2024(Q4)Sep 30, 2024(Q3)Jun 30, 2024(Q2)Mar 31, 2024(Q1)Dec 31, 2023(FY)Sep 30, 2023(Q4)Sep 30, 2023(Q3)Jun 30, 2023(Q2)Mar 31, 2023
Total revenue 5,268.84%1M-87.40%18.63K000-50.00%18.63K-57.76%147.81K-40.63%37.26K-40.63%36.85K-61.77%36.45K
Operating revenue 5,268.84%1M-87.40%18.63K--0--0--0-50.00%18.63K-57.76%147.81K-40.63%37.26K-40.63%36.85K-61.77%36.45K
Cost of revenue
Gross profit
Operating expense 196.68%3.85M-37.34%11.87M-12.76%3.17M-10.72%3.53M-32.14%3.87M-77.03%1.3M-36.91%18.94M-51.11%3.64M-50.16%3.95M-31.36%5.7M
Selling and administrative expenses 200.46%1.96M-13.96%6.13M10.01%1.97M16.79%1.8M-9.73%1.7M-65.67%653.46K-16.90%7.13M-22.50%1.79M-32.35%1.54M-0.83%1.88M
-General and administrative expense 200.46%1.96M-13.96%6.13M10.01%1.97M16.79%1.8M-9.73%1.7M-65.67%653.46K-16.90%7.13M-22.50%1.79M-32.35%1.54M-0.83%1.88M
Research and development costs 192.85%1.89M-51.44%5.74M-34.94%1.2M-28.32%1.73M-43.21%2.17M-82.81%644.04K-44.90%11.81M-64.04%1.84M-57.35%2.41M-40.41%3.82M
Operating profit -122.81%-2.85M36.95%-11.85M11.85%-3.17M9.88%-3.53M31.71%-3.87M77.21%-1.28M36.66%-18.79M51.20%-3.6M50.23%-3.92M31.00%-5.66M
Net non-operating interest income expense
Other net income (expense) -238.53%-152.88K11,109.40%4.41M158.47%44.78K173.52%23.11K183,946.55%4.23M57.09%110.36K23.64%-40.08K-31.21%-76.59K-220.93%-31.43K-234.13%-2.3K
Gain on sale of security -238.53%-152.88K310.33%84.29K158.47%44.78K173.52%23.11K-3,979.90%-93.96K57.09%110.36K23.64%-40.08K-31.21%-76.59K-220.93%-31.43K-234.13%-2.3K
Other non- operating income (expenses) ------4.33M--0------4.33M--------------------
Income before tax -156.93%-3M60.51%-7.44M14.91%-3.13M11.18%-3.51M106.45%365.43K78.92%-1.17M36.64%-18.83M50.55%-3.68M49.90%-3.95M30.96%-5.67M
Income tax 158.4K0
Net income -170.49%-3.16M60.51%-7.44M14.91%-3.13M11.18%-3.51M106.45%365.43K78.92%-1.17M36.64%-18.83M50.55%-3.68M49.90%-3.95M30.96%-5.67M
Net income continuous Operations -170.49%-3.16M60.51%-7.44M14.91%-3.13M11.18%-3.51M106.45%365.43K78.92%-1.17M36.64%-18.83M50.55%-3.68M49.90%-3.95M30.96%-5.67M
Minority interest income
Net income attributable to the parent company -170.49%-3.16M60.51%-7.44M14.91%-3.13M11.18%-3.51M106.45%365.43K78.92%-1.17M36.64%-18.83M50.55%-3.68M49.90%-3.95M30.96%-5.67M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders -170.49%-3.16M60.51%-7.44M14.91%-3.13M11.18%-3.51M106.45%365.43K78.92%-1.17M36.64%-18.83M50.55%-3.68M49.90%-3.95M30.96%-5.67M
Basic earnings per share 36.59%-1.5692.18%-11.3578.16%-3.6776.27%-5.6101.06%0.6498.25%-2.4687.95%-145.1394.29%-16.803992.63%-23.682.03%-60.4
Diluted earnings per share 36.59%-1.5692.18%-11.3578.16%-3.6776.27%-5.6100.93%0.5698.25%-2.4687.95%-145.1394.29%-16.803992.63%-23.682.03%-60.4
Dividend per share
Currency Unit USDUSDUSDUSDUSDUSDUSDUSDUSDUSD
Accounting Standards US-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions --Unqualified Opinion with Explanatory Notes--------Unqualified Opinion with Explanatory Notes------

Trending Stocks

Top Gaining Chinese Stocks Top Gaining Chinese Stocks
No. Symbol % Chg
HENDERA
831152
+30.00%
Hengerda New Materials
300946
+20.01%
Fujian Nebula Electronics.,Ltd
300648
+20.00%
4
Cubic Digital Technology
300344
+19.98%
5
HNAC Technology
300490
+19.95%
Log In for the Full List
Unlock Now
Investment Course
Top 5 Industries for Stock Trading under Trump's Second Term
Stocks & Industries to Watch Under Trump's Second Presidency
With mooomoo, find out which stocks and industries may benefit from Trump's second presidency, based on his first administration's track record.
Trump's comeback to the Office
Following Trump's Policies to Seek Investment Opportunities
Discussing
Trump 2.0 Era: How will global markets evolve?
🎙️Discussion: 1. How will tariff policies affect the movement of key assets such as U.S. stocks, gold, and Bitcoin? 2. Given this context, Show More
MicroStrategy Q4 2024 earnings conference call